secwatch.observer — SEC 8-K summary
======================================

Issuer:     Merck & Co., Inc. (MRK)
CIK:        0000310158
Form:       8-K
Filed at:   2022-07-28T23:59:59+00:00
Accession:  0001104659-22-083410
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Merck Q2 revenue up 28% to $14.6B; non-GAAP EPS $1.87 vs $0.61; raises 2022 sales guidance
--------------------------------------------------------------------------------

- KEYTRUDA sales rose 26% to $5.3B; GARDASIL/GARDASIL 9 up 36% to $1.7B, driven by China demand.
- LAGEVRIO contributed $1.2B in Q2 sales; full-year outlook maintained at $5.0-$5.5B.
- GAAP EPS $1.55 vs $0.48; non-GAAP EPS $1.87 vs $0.61, reflecting strong operational performance.
- Company raised and narrowed 2022 full-year sales guidance to $57.5-$58.5B (18-20% growth).
- Non-GAAP EPS guidance narrowed to $7.25-$7.35; includes ~$0.09 impact from Orion upfront payment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/310158/000110465922083410/0001104659-22-083410-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/310158/000110465922083410/tm2221828d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-083410

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer